A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2015
Price : $35 *
At a glance
- Drugs Temsirolimus (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 06 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Dec 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.